255 publications
Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults
Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the ...
Pitolisant (Wakix®) for the treatment of narcolepsy in adults
Zorginstituut Nederland carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug currently ...
Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea
Zorginstituut Nederland carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is interchangeable with ...
Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions
Zorginstituut Nederland carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be altered. ...
Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer
Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally ...
Organisation structure National Health Care Institute
Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)
Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal product ...
Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer
Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic breast cancer. ...
Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)
Zorginstituut Nederland carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, Yescarta®) for the ...
Tisagenlecleucel (Kymriah®) for the treatment of DLBCL
Zorginstituut Nederland has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to its ...